RxDoctor Payments Data

Charn Nandra, MD

Cardiovascular Disease · Steubenville, OHNPI 1558358317

Payments from drug & device makers

$795in general payments, 2019–2025

Across 44 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$199
  • AstraZeneca$165
  • E.r. Squibb & Sons, L.L.C.$98
  • Novo Nordisk$76
  • Abiomed$39
  • Merck$31
  • plus $186 from 10 others

What the payments were for

  • Food & beverage$78198%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$795 in reported general payments places this provider in the 35th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$241,123
Medicare patients
765
Services billed
4,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban525$462,021
XareltoRivaroxaban328$295,868
EntrestoSacubitril/Valsartan249$278,518
JardianceEmpagliflozin182$157,193
BrilintaTicagrelor130$82,202
Repatha SureclickEvolocumab39$43,638
Ranolazine ErRanolazine264$29,881
Praluent PenAlirocumab21$20,652
FarxigaDapagliflozin Propanediol18$18,954
MultaqDronedarone Hcl11$8,040
Carvedilol1,038$7,320
Propafenone Hcl124$5,955
Potassium Chloride359$5,920
ClopidogrelClopidogrel Bisulfate583$5,466
Metoprolol Succinate356$4,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$295,868328 claims
NovartisEntresto$15$278,518249 claims
Boehringer IngelheimJardiance$15$157,193182 claims
AstraZenecaBrilinta, Farxiga$165$101,156148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Steubenville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →